SWARM study
SWARM – Small robots With collective behaviour as AI-driven cancer therapies; building Regulations for future nanoMedicines
Background
Cancer Nanomedicine
Cancer occurs when abnormal cells divide in an uncontrolled way. Many cancers can be cured. But in some people cancer can return. Cancer drugs, such as chemotherapy, need to be able to kill all the cancer cells, but this means they can also kill healthy cells.
Nanomedicine is the medical application of nanotechnology which works on tiny scales called ‘nanometres’ (one-billionth of a metre). Nanoparticles are nanosized particles that can assist the delivery of chemotherapy drugs to cancer cells. Scientists and Engineers can use simulations for selecting nanoparticles so drugs can more effectively reach the tumour while avoiding side effects.
Nanoswarms
Using simulations, scientists and engineers are working on adding swarm behaviour (present in social animals such as birds, ants, fish and termites) to nanoparticles and tiny robots (nanobots). Nanoswarms are multiple nanoparticles or nanobots that can interact with each other or their environment to achieve a task (e.g. deliver chemotherapy to a tumour without killing healthy cells), exhibiting collective behaviour inspired by swarm behaviour.
SWARM study – aim & research question
This project is investigating the ethics and regulations of the first in-human clinical trial of nanoswarms. We will be using interviews initially and focus groups in the next phase to explore the attitudes of stakeholders towards this swarm technology in healthcare, combined with ethical/legal analysis to consider how swarm medicine should be regulated in clinical trials.
The aim is to explore how nanoswarm medicine should be regulated once this technology is available for first-in human clinical trials.
Researchers
This study is being organised by Matimba Swana, PhD student in the Trustworthy Autonomous Systems in Functionality Node and Academic Supervisors; Dr. Sabine Hauert, Reader (Associate Professor) in Swarm Engineering and Prof. Jonathan Ives, Professor of Empirical Bioethics & Deputy Director of Centre for Ethics in Medicine.
Would you like to participate?
If you are aged 18 or over, we would love to hear from you. For the interviews we are looking for oncology healthcare professionals or oncology patients or those working in drug delivery regulation or in nanomedicine research. You do not need to have any previous knowledge of nanoswarms to participate as we will show you case studies to introduce you to the technologies.
Your contribution would be very helpful! For more details please contact Matimba Swana at matimba.swana@bristol.ac.uk OR complete this Expression of Interest form for interviews.
We are still in the first phase of this study, so will not start interviews until later in the year, but please complete the Expression of Interest form for interviews and we will be in touch to schedule an interview. We will start recruiting for focus groups in early 2023.
Five fun facts
The SWARM study is part of a larger UKRI-funded PhD which is part of the Trustworthy Autonomous Systems Node in Functionality research program, which is a multidisciplinary collaboration between ethicists, sociologists, computer scientists and engineers working together to produce guidelines for the development of trustworthy autonomous systems with evolving functionality.
Research Ethics Approval
This project has been reviewed and approved by the University of Bristol Faculty of Engineering Research Ethics Committee (Ref: 11141).
Find out more
Before Participating:
MMI Molecular Machines and Industries AG installed a CellCut system at the A.I. Virtanen Institute for Molecular Sciences at the University of Eastern Finland in Kuopio on 21 and 22 October 2026.
A study led by Imperial College London compared five wastewater concentration methods. Nanotrap Microbiome A Particles showed the most consistent recovery across pathogens and the lowest equipment cost at approximately $8,200.

Mecwins has described its AVAC technology, which labels target proteins with plasmonic nanoparticles and counts each one individually by dark-field micro-spectrophotometry. The AVAC Analyzer reaches femtogram-range sensitivity.
This week in nanotech
$751.8M raised
6 funding rounds · 38 deals tracked
New products
Orion Sputtering Deposition SystemsAJA International Featured
DLS-1 Mass Spectrometer for Fusion Gas AnalysisHiden Analytical Featured
NanoFlow® S1-20LevidianMarket insights
Last 30 days: Quantum Technologies drew the most money: $3.18B.
Money raised per month
Behind the deal
Who led Institut de Microelectronica de Barcelona (IMB-CNM, CSIC)’s $185.7M Grant?
See the investors with Insights Pro →